ArticleAmerican journal of translational research2023
Performance of Bakri balloon tamponade in controlling postpartum hemorrhage.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Chitosan-covered tamponade for the treatment of postpartum hemorrhage: a registry-based cohort study assessing outcomes and risk factors for treatment failure.BMC pregnancy and childbirth · 2025Article
- Timely use of Bakri intrauterine balloon tamponade contributes to the effectiveness in controlling severe postpartum hemorrhage.Experimental and therapeutic medicine · 2024Article
- Efficacy of Bakri Intrauterine Balloon in Managing Postpartum Hemorrhage: A Comparative Analysis of Vaginal and Cesarean Deliveries with Placenta Accreta Spectrum Disorders.Medical science monitor : international medical journal of experimental and clinical research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveBakri balloon tamponade (BBT) is currently being used worldwide. This study aimed to explore the real-world performance of BBT for the treatment of postpartum hemorrhage (PPH).
methodsA total of 279 women with PPH who failed to respond to first-line conservative management and received BBT were consecutively recruited, reflecting authentic settings. The maternal baseline clinical data, PPH management, and perinatal outcome were recorded. In addition, the perinatal outcomes of women with pre-BBT blood loss <1000 mL were compared to those with ≥1000 mL. Finally, the factors related to pre-BBT blood loss ≥1000 mL were analyzed by logistic regression.
resultsThe mean gestational age of all recruited women was 39.03±1.98 weeks, with a primipara proportion of 68.82%, a vaginal delivery rate of 60.93%, a uterine atony rate of 74.91%, and placenta accreta rate of 53.05%. Perinatal outcomes showed a hemostasis success rate of 88.89%, a transvaginal BBT placement rate of 80.29%, and a blood transfusion rate of 65.95%. Compared to women with blood loss <1000 mL (33.33%), women with blood loss ≥1000 mL (66.67%) showed a lower proportion of gestational hypertension (
conclusionsBBT is effective in stopping PPH among women with massive blood loss in documented settings.
Indexed as
Identifiers
37056856PMC10086883W4365482540What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.